News

When bitcoin surged past $100,000 this month, many crypto skeptics felt a pang of something: Envy? Self-doubt? Resignation?

Money market account rates vary widely. So which banks are offering the best money market account rates today? Find out here.

A Chinese fund manager has touted its fund's cryptocurrency exposure in an effort to draw investors amid a historic bitcoin boom, even as Beijing maintains a hostile stance towards the digital assets. A fund advertisement that read "Cryptocurrencies soaring, start investing with 10 yuan" was spotted on Alipay, Chinese fintech giant Ant Group's mobile wallet app, crypto-focused outlet Wu Blockchain reported on Thursday. The fund, a Qualified Domestic Institutional Investor (QDII) fund operated by

Here is a 2-minute breakdown of everything important that happened in crypto today.

As of Thursday, the average target for the S&P 500 index to close at the end of 2025 was 6,678.18, which would be a 10% rise from the index's Thursday close.

Elon Musk says the Securities and Exchange Commission wants him to pay a penalty or face charges involving what he disclosed — or failed to disclose — about his purchases of Twitter stock before he bought the social media platform in 2022. In a letter posted by Musk on the platform now called X, his lawyer Alex Spiro tells the outgoing SEC chairman, Gary Gensler, that the commission's demand for a monetary payment is a “misguided scheme” that won't intimidate Musk. The letter also alleges that the commission reopened an investigation this week into Neuralink, Musk's computer-to-human brain interface company.

On Thursday, Repare Therapeutics Inc (NASDAQ:RPTX) revealed data from its MYTHIC Phase 1 gynecologic expansion trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) for endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers. As of the data cut-off date of November 14, 51 evaluable patients were enrolled in the gynecologic cancer expansion cohort of the MYTHIC trial. Across all tumor types treated at the optimized RP2D (n=67),